Merck KGaA, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, announced that the two innovative fertility technologies Gavi and Geri have cleared a major milestone, achieving CE Mark certification. Merck KGaA recently signed a global collaboration agreement with Genea Biomedx, the manufacturer of both products.

With this partnership, Merck KGaA, received global marketing and commercialization rights to Genea Biomedx's product portfolio. All products will be provided through Merck KGaA's fertility technologies unit.

The achievement of regulatory clearance allows Gavi and Geri to be made available for sale in the European Union.

Conceived through the fertility knowhow of Genea Biomedx's parent company Genea, the instruments are designed to provide solutions to some of the challenges involved in successful fertility treatment.

Gavi is the world's first automated vitrification instrument which uses an automated, standardized protocol aiming to ensure consistent results in blastocyst vitrification. Geri is a benchtop incubator that includes a camera system that allows scientists to view the embryo without repeatedly removing it from its optimal environment.

Gavi and Geri are on display and available to order at ESHRE in Portugal starting from June 14-17, 2015.

Genea Biomedx creates and manufactures practical, accessible and precise fertility technologies that help standardise and automate fertility treatment. Its unique relationship with Genea Fertility means that Genea Biomedx is a manufacturer that truly understands the customers' perspective. As a result Genea Biomedx has developed the world's first automated vitrification instrument, and has other projects well advanced in the product pipeline.